SCHEMBL1403500

SCHEMBL1403500

COC(=O)c1cccc(CN(C)C(=O)OC(C)(C)C)c1C(=O)OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38
MAPK10 P53779 1/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
CA12 O43570 1/20 0.38
CA7 P43166 1/20 0.38
CA14 Q9ULX7 1/20 0.38
HSD17B10 Q99714 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
HTR2C P28335 1/20 0.36
SLC6A4 P31645 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1424499 0.92 HTR2C (0.38) LMNAALDH1A1MAPK8MAPK9MAPK10
SCHEMBL1424286 0.88 ALDH1A1 (0.38) LMNAALDH1A1MAPK8MAPK9MAPK10
SCHEMBL1424288 0.88 HCRTR1 (0.39) LMNAALDH1A1HSD17B10L3MBTL1KDM4E
SCHEMBL14275285 0.86 ALDH1A1 (0.35) LMNAALDH1A1MAPK8MAPK9MAPK10
SCHEMBL1403561 0.81 HTR2C (0.40) L3MBTL1HTR2CSLC6A4GLSKMT2A
SCHEMBL1424508 0.80 TSHR (0.43) LMNAALDH1A1CA1CA2CA9
SCHEMBL3107925 0.80 MAPK8 (0.39) LMNAALDH1A1MAPK8MAPK9MAPK10
SCHEMBL8017533 0.78 HTR2C (0.47) L3MBTL1HTR2CSLC6A4GLSKMT2A
SCHEMBL2381485 0.77 KCNA5 (0.49) LMNAALDH1A1MAPK8MAPK9MAPK10
SCHEMBL31407207 0.77 ALDH1A1 (0.43) LMNAALDH1A1MAPK8MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3327013-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2019-04-24 EP disclosed
EP-3327013-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS Celgene Corporation (US) 2018-05-30 EP disclosed
EP-3061758-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2018-01-31 EP disclosed
US-9801868-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2017-10-31 US disclosed
US-20160346264-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2016-12-01 US disclosed
US-9447070-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2016-09-20 US disclosed
EP-3061758-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS Celgene Corporation (US) 2016-08-31 EP disclosed
EP-2749559-B1 5-substituted isoindoline compounds CELGENE CORP (US) 2016-04-27 EP disclosed
EP-2291365-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2015-03-11 EP disclosed
US-20150005303-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2015-01-01 US disclosed
WO-2009145899-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2009-12-03 WO disclosed
CN-101534820-A N-methylaminomethylisoindole compounds and compositions comprising and methods of using the same CELGENE CORP (US) 2009-09-16 CN disclosed
EP-2076260-A1 N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2009-07-08 EP disclosed
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2009-06-04 US disclosed
EP-2057143-A2 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2009-05-13 EP disclosed
US-20080214615-A1 N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same CELGENE CORPORATION 2008-09-04 US disclosed
US-20080214615-A1 N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same CELGENE CORPORATION 2008-09-04 US disclosed
US-20080214615-A1 N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same CELGENE CORPORATION 2008-09-04 US disclosed
WO-2008033567-A1 N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2008-03-20 WO disclosed
WO-2008027542-A2 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214615-A1 N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same INMT, HNMT, TPMT LMNA 996/4885ALDH1A1 1086/4885MAPK8 3966/4885
US-20160346264-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 LMNA 2252/4885ALDH1A1 403/4885MAPK8 4082/4885
US-20150005303-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 LMNA 2252/4885ALDH1A1 403/4885MAPK8 4082/4885
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 LMNA 2252/4885ALDH1A1 403/4885MAPK8 4082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.